Clinical Trial

LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma

Study acronym: Canbiome2
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is being done to answer the following question: Can the chance of melanoma growing or spreading be lowered by receiving a treatment called LND101 for Fecal Microbiota Transplant (FMT) in addition to the usual immunotherapy treatment called Immune Checkpoint Blockade (ICB)? FMT treatment changes the bacteria in your gut called the microbiome.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2024-09-30; most recent amendment 2026-05-11.
Status change: Not Yet Recruiting → Recruiting 2025-03-28
Trial Details
NCT Number NCT06623461
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Canadian Institutes of Health Research (CIHR), Canadian Cancer Society (CCS), Weston Family Foundation
Conditions Melanoma
Enrollment 128 participants
Start Date 2025-04-07
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-12